Nexentis Technologies Inc. NXTS

Nexentis Technologies Inc. announced that Prof. Dan T. Major has joined the Scientific Advisory Board of its subsidiary MitoCareX Bio Ltd. Major, a Bar-Ilan University professor specializing in computational chemistry and in silico drug discovery, will advise on computational chemistry methods and in silico drug-discovery strategies to prioritize discovery programs. MitoCareX aims to expand internal computational capabilities to guide program prioritization and previously started a drug-discovery collaboration with AI lab Boltz. Nexentis notes it owns 100% of MitoCareX and pursues renewable energy assets under a Ready to Build model, leading four European solar projects via Solterra Renewable Energy Ltd. The release underscores Nexentis's dual focus on drug discovery through MitoCareX and renewable energy assets, with customary forward-looking statements and investor contact. Strengthens internal drug-discovery capabilities and prioritization with a notable, but not transformative, advisory appointment.

Nexentis Technologies Inc. said its wholly owned subsidiary MitoCareX Bio Ltd. is evaluating additional commercially available approaches for obtaining proteins used in its in-vitro research, aiming to broaden access to research materials and increase flexibility as its discovery programs progress. The assessment is early stage and no approach is guaranteed to be adopted or beneficial. CEO Dr. Alon Silberman said the company is methodically exploring tools to enhance the quality and consistency of in-vitro research while preserving flexibility. MitoCareX is building a focused drug-discovery platform integrating biology, chemistry and computation. Nexentis owns 100% of MitoCareX and, separately, has an investment strategy in European renewable energy, including four RTB solar projects led by Solterra Renewable Energy Ltd. The release contains standard forward-looking statements and risk factors; no guaranteed outcomes are promised. Enhances research flexibility and potential toolset, but success depends on uncertain adoption and no immediate financial impact.

Nexentis Technologies Inc. subsidiary MitoCareX Bio advances SLC transporter drug discovery through broad analysis and an international AI initiative. Subsidiary progress in drug discovery may support product innovation and market positioning without altering overall company trajectory.

Nexentis Technologies Inc. (NXTS) shares rose after the company reached a monetisation agreement for its solar project. Solar project monetisation supplies cash inflow and lifts share price but scale remains unspecified so overall trajectory impact stays moderate.

Nexentis Technologies monetizes part of its Melz Solar investment at a $14.5 million project valuation, achieving a significant premium to the initial investment. Monetization at premium directly improves cash position and reported financial results.

Nexentis Technologies announces an international AI drug discovery initiative between MitoCareX Bio and Boltz to accelerate novel SLC small-molecule discovery. Announcement of major AI drug discovery initiative marks significant strategic expansion likely to alter Nexentis competitive trajectory.

Nexentis Technologies Inc.'s subsidiary MitoCareX Bio completed broad analysis of SLC transport proteins to support discovery of treatments for hard-to-treat cancers and metabolic diseases. Subsidiary research milestone advances drug discovery pipeline in core oncology and metabolic disease areas with moderate positioning effects.

Nexentis Technologies Inc. (NXTS) announced MitoCareX Bio achieved a key R&D milestone by generating a substantially improved hit molecule advancing toward pre-clinical development. Early-stage R&D progress at subsidiary offers moderate potential upside for pipeline value and investor sentiment without immediate financial effects.

Nexentis Technologies Inc. (NXTS) announces optimization of a hit molecule at MitoCareX Bio, marking a key milestone in drug discovery. Hit molecule optimization advances Nexentis's biotech pipeline, signaling significant progress that could boost investor sentiment and competitive positioning.

Nexentis Technologies Inc. (NXTS) announces U.S. trademark registration approval for MitoCareX’s algorithm platform MITOLINE™. U.S. trademark approval for MITOLINE™ bolsters Nexentis Technologies' IP protection and competitive edge in algorithm platforms.

N2OFF, Inc. (NITO) announces corporate rebranding to Nexentis Technologies, positioning itself as an innovative AI and data-driven computational biotech company. Rebranding to Nexentis Technologies marks a major strategic shift toward AI-driven biotech, likely enhancing market perception and long-term growth prospects.

MitoCareX Bio has reported successful in vitro results demonstrating that MITOLINE™-powered small molecules exhibit anti-inflammatory potential for diseases related to metabolic syndrome. These findings suggest a promising avenue for therapeutic development targeting inflammation associated with metabolic disorders. The successful in vitro results indicate significant potential for product innovation and market positioning in a growing therapeutic area.

N2OFF, Inc. (NITO) highlights its co-founder's innovative research on mitochondrial carriers under microgravity and cosmic radiation conditions through the MitoCareX Bio project. This research aims to explore the effects of spaceflight on mitochondrial function, potentially leading to advancements in health and performance in space environments. The findings could have implications for both space exploration and terrestrial health applications. Research on mitochondrial carriers in space could lead to significant advancements in health technologies and applications, impacting NITO's strategic direction and market position.

MitoCareX Bio has announced positive in vitro results from its mitochondrial carrier small molecule platform, which could enhance the understanding and treatment of mitochondrial diseases. This development is expected to advance the company's research and potential therapeutic applications, signaling progress in their innovative approach to mitochondrial health. Positive in vitro results could significantly influence N2OFF's future product development and market positioning.

N2OFF, Inc. (NITO) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company. Investors are closely monitoring NITO's performance as it could signal potential opportunities or risks in the near future. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

N2OFF, Inc. (NITO) highlights the pioneering research of co-founder Dr. John Smith on mitochondrial carriers and their role in mitigating stress conditions during spaceflight. This research aims to enhance astronaut health and performance, potentially leading to advancements in space exploration and related biotechnologies. The findings could have significant implications for understanding mitochondrial function in extreme environments. Research on mitochondrial carriers in spaceflight stress conditions could lead to significant advancements in astronaut health and biotechnologies.

N2OFF, Inc. (NITO) has made a $340,000 payment to secure improved terms in the Flag Solar Energy Initiative, which is expected to enhance the company's profit stake in the project by approximately $1.7 million. This strategic move aims to strengthen NITO's position in the solar energy sector. The payment is a significant strategic move that could enhance profitability and market positioning in the solar energy sector.

N2OFF, Inc. (NITO) has achieved significant de-risking milestones in Europe, unlocking approximately $1.69 million in value in Germany and Italy. These advancements are expected to accelerate the company's momentum in the renewable energy sector, enhancing its competitive positioning and financial outlook. The milestones achieved are likely to significantly impact NITO's future performance and investor sentiment in the renewable energy market.

N2OFF, Inc. (NITO) announced that MitoCareX has successfully identified hit compounds and is moving forward with the nomination of preclinical candidates. This development marks a significant step in the company's research and development efforts, potentially leading to advancements in therapeutic options. The identification of hit compounds and preclinical candidate nomination is a significant advancement in NITO's drug development pipeline.

N2OFF, Inc. (NITO) has successfully completed a merger with a cancer drug discovery company that focuses on developing treatments for challenging pancreatic and lung cancers. This strategic move aims to enhance NITO's capabilities in oncology and expand its product pipeline, potentially leading to significant advancements in cancer treatment. The merger is a major strategic move that could significantly enhance NITO's competitive position in the oncology market.

SciSparc has completed the sale of its majority-owned subsidiary MitoCareX to N2OFF, Inc. (NITO). This acquisition aims to enhance drug discovery efforts targeting resistant cancers, including pancreatic and non-small cell lung cancer. The move is expected to bolster NITO's capabilities in developing innovative cancer therapies. Acquiring MitoCareX is a significant strategic move that could enhance N2OFF's position in the competitive oncology market.

N2OFF, Inc. (NITO) has successfully completed its merger with a drug discovery company focused on developing treatments for resistant cancers, including pancreatic and non-small cell lung cancer. This strategic move aims to enhance NITO's capabilities in addressing significant medical challenges and expanding its portfolio in the oncology sector. The merger is expected to significantly enhance NITO's strategic position and product offerings in a critical therapeutic area.

N2OFF, Inc. (NITO) has regained compliance with the Nasdaq minimum bid price requirement after its stock price rose above the $1 threshold for 10 consecutive trading days. This achievement follows a period of non-compliance that could have led to delisting. The company expressed its commitment to maintaining compliance and enhancing shareholder value moving forward. Regaining compliance with Nasdaq requirements positively influences market sentiment and stability but does not fundamentally change the company's trajectory.

N2OFF, Inc. (NITO) shareholders have approved a merger with SciSparc’s majority-owned subsidiary, MitoCareX, which focuses on drug discovery for resistant cancers, including pancreatic and non-small cell lung cancer. This strategic move aims to enhance NITO's capabilities in addressing significant medical challenges in oncology. The merger with MitoCareX is a significant strategic move that could enhance NITO's market position and investor sentiment in the oncology sector.

N2OFF, Inc. (NITO) stockholders have approved a merger with a drug discovery company focused on developing treatments for resistant cancers, including pancreatic and non-small cell lung cancer. This strategic move aims to enhance NITO's capabilities in addressing significant medical challenges and expanding its market presence in oncology. The merger is a significant strategic move that could enhance NITO's competitive positioning in the oncology market.

N2OFF, Inc. (NITO) has successfully executed solar and energy storage initiatives across Europe, highlighting its commitment to sustainable energy solutions. The company reported significant progress in its projects, which are expected to enhance its operational capabilities and market presence in the renewable energy sector. NITO's strategic focus on these initiatives aligns with the growing demand for clean energy alternatives in Europe, positioning the company for future growth. Successful execution of solar and energy storage initiatives is likely to significantly enhance NITO's market position and investor sentiment.

N2OFF, Inc. (NITO) has announced a reverse stock split aimed at increasing the per-share price of its common stock. The company believes this move will enhance its appeal to institutional investors and improve its market position. The reverse split will be executed at a ratio of 1-for-10, meaning every ten shares will be consolidated into one share. This decision comes as part of NITO's strategy to comply with listing requirements and attract more investment. The company expects the reverse split to take effect shortly, pending regulatory approval. The reverse stock split may influence investor sentiment and market perception, but its overall impact on the company's long-term trajectory is expected to be limited.

N2OFF, Inc. (NITO) is set to expand its Melz Solar Project by incorporating battery storage solutions. This initiative aims to enhance energy efficiency and reliability, aligning with the company's commitment to sustainable energy practices. The expansion is expected to bolster the project's capacity and contribute to the growing demand for renewable energy sources. The expansion of the Melz Solar Project with battery storage is a significant strategic move that could enhance NITO's competitive positioning in the renewable energy market.

N2OFF, Inc. (NITO) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company. Investors are closely monitoring NITO's performance as it could signal potential opportunities or risks in the near future. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.

N2OFF, Inc. has completed a $1.2 million investment as part of a $2.7 million commitment to finance two Battery Energy Storage Systems (BESS) in Sicily, Italy, each with a capacity of 98MWp/392MWh. The projects, valued at up to $13.5 million, aim to enhance grid stability and have secured preliminary grid connection approvals. CEO David Palach expressed optimism about achieving Ready-to-Build status within 18-24 months, citing strong growth in Italy's solar market driven by government incentives. N2OFF is focused on sustainable energy solutions and has invested in various projects in the EU. The investment in significant battery storage projects positions N2OFF to capitalize on the growing demand for renewable energy solutions in Italy.